

PLANNING

LEGAL NOTICES

Environmental Protection Agency Acts, 1992 to 2007
Genetically Modified Organisms (Deliberate Release) Regulations, S.I. No 500 of 2003
PROPOSED DELIBERATE RELEASE OF A GENETICALLY MODIFIED ORGANISM

In accordance with the above legislation, SparingVision, headquartered at 5 avenue Percier, 75008 Paris, France, has submitted a notification to the Environmental Protection Agency (EPA) of a proposal to conduct a clinical trial in Ireland using a Genetically Modified Organism (GMO).

Description and purpose of the GMO and clinical trial SPVN20 or AAVi-GIRK1(F137S) is a nonpathogenic recombinant adeno-associated virus (vector) containing an optimized version of the human gene of G protein-gated inwardly rectifying potassium (GIRK) channel 1. The vector has been engineered to target cone photoreceptors following an intravitreal injection. The purpose of this clinical trial is to study SPVN20 (or AAVi-GIRK1(F137S)) for the treatment of patients with no light perception (NLP) due to end-stage rod-cone dystrophy (RCD), and who retain dormant foveal cone photoreceptors (i.e., cells that have lost their ability for phototransduction). A target of nine (9) subjects will be enrolled in this study worldwide. SPVN20 will be administered to patients in the eye via the intravitreal route. In the SPVN20 treatment approach, GIRK1(F137S) transgene is expressed in dormant foveal cone photoreceptors, to restore their ability for phototransduction. Following SPVN20 administration to patients with NLP due to end-stage RCD, GIRK1(F137S) expression in dormant cones could provide an alternative hyperpolarization mechanism in response to light stimulus, in the form of an alternative phototransduction cascade, allowing cone reactivation. Proposed location of the clinical trial
One (1) Irish site, the Royal Victoria Eye and Ear Hospital located at Adelaide Road, Dublin 2, Ireland, will participate in the clinical trial.
Date of the proposed clinical trial. The notification covers the treatment of clinical trial patients at the named location between September 2025 and September 2031. The clinical trial aims to enroll a total of nine (9), of which two (2) patients enrolled in Ireland.
In accordance with article 16(1) of the Genetically Modified Organisms (Deliberate Release) Regulations, S.I. No 500 of 2003, any person or body may make representations in writing, which will be no later than 28 days from the date of publication of this notice. Representation will be to the Environmental Protection Agency, Office of Environmental Sustainability, P.O. Box 3000, Johnstown Castle Estate, Co Wexford, Ireland and will be subject to a fee of €10 (guidance on fee payment may be obtained by writing to gmo@epa.ie). Further information on the proposed deliberate release may be obtained from the Environmental Protection Agency.